This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.0 | Special Copayment Reduction: V117 |
| B. Synonyms | Andersen disease, glycogen storage disease type IV (GSD type IV), Branching enzyme deficiency, GBE1 deficiency, Polyglucosan body disease, Adult polyglucosan body disease (APBD), Amylopectinosis |
| C. Adult onset | Likelihood of first onset in adulthood high — adult polyglucosan body disease (APBD) is a GBE1 deficiency-related neurological syndrome that first presents in the 40s–60s with progressive upper and lower motor neuron abnormalities, bladder dysfunction, and peripheral neuropathy. APBD is a phenotype clinically completely different from classic Andersen disease (hepatic form). |
| 1. History | 1956 Andersen, first description of GSD IV → 1966 Brown/Brown-type polyglucosan body studies → 1989 independent description of APBD → 1993 cloning of the GBE1 gene → introduction of liver transplantation → gene therapy research under way. |
| 2. Causes | GBE1 gene mutation → glycogen branching enzyme (GBE) deficiency → accumulation of abnormal polyglucosan bodies (PGB) → damage to liver, myocardium, nerves, and muscle. Autosomal recessive. |
| 3. Genetics | GBE1: 3p12.3, 16 exons. Hepatic (classic) form: driven by loss-of-function variants. APBD: the c.986A>C (p.Tyr329Ser) founder variant accounts for ~90% of APBD in Ashkenazi Jews. Non-Jewish APBD: various variants. Neurological phenotype tends to predominate when residual GBE activity is present. |
| 4. General epidemiology | GSD IV: about 3% of all GSD, prevalence ~1/600,000–1/1,000,000, very rare. Classic (hepatic) form: mainly childhood onset. APBD: mainly adult onset, frequent in Ashkenazi Jews. Only a small number of cases reported worldwide. |
| 5. Pathophysiology | GBE deficiency → inability to form branches during glycogen synthesis → accumulation of amylopectin-like, linear-chain polyglucosan bodies → recognized as foreign material, inducing immune and inflammatory responses → liver cirrhosis, cardiomyopathy, nerve damage. |
| 6. Symptoms | Classic form (infancy to childhood): hepatomegaly, liver cirrhosis, liver failure, splenomegaly, failure to thrive. Neuromuscular variant: severe hypotonia at birth, respiratory failure. APBD (adult): limb spasticity and weakness, bladder dysfunction, peripheral neuropathy, dementia. |
| 7. Signs | Hepatomegaly, splenomegaly, ascites (in cirrhosis), abnormal liver function. Neuromuscular variant: generalized hypotonia, respiratory failure. APBD: coexisting upper and lower motor neuron signs, bladder dysfunction, abnormal nerve conduction. PAS-positive polyglucosan bodies (histology). |
| 8. Screening | Newborn screening not standard. Genetic testing based on family history. Included in differential diagnosis panels for causes of infantile cirrhosis. APBD: GBE1 gene analysis in the differential workup of adult neuropathy. Measurement of leukocyte GBE enzyme activity. |
| 9. Diagnosis | Measurement of GBE enzyme activity in leukocytes or liver/muscle biopsy. GBE1 gene analysis. Liver biopsy: PAS-positive polyglucosan deposits (zymogram pattern), fibrosis. APBD: PAS-positive polyglucosan bodies on skin nerve or brain/spinal cord biopsy. MRI (brain white matter abnormalities). |
| 10. Treatment | Classic hepatic form: liver transplantation (corrects liver symptoms; muscle and nerve abnormalities persist). Neuromuscular variant: symptomatic respiratory support. APBD: some trials of dietary fat therapy such as triheptanoin, rehabilitation therapy. No specific therapy. Gene therapy at the research stage. |
| 11. Prognosis | Classic (hepatic) form: many die before age 5 without liver transplantation. Survival is possible after liver transplantation, but muscle and myocardial abnormalities persist or progress. APBD: progresses slowly, with wheelchair use and dementia developing. Variant (neuromuscular) form: poor prognosis. |
| 12. Prevention | Genetic counseling and prenatal diagnosis. Prevention of complications after liver transplantation. Maintenance of physical activity and rehabilitation in APBD. Myocardial monitoring. Pursuit of gene therapy development. |
| 13. References | Bruno C et al. Ann Neurol 2004 and 9 others |
The history of Andersen disease (GSD type IV) began in 1956, when the American pediatrician Dorothy Hansine Andersen described massive accumulation of an abnormal amylopectin-like polysaccharide in the liver tissue of a child who died of liver cirrhosis and liver failure in infancy. Andersen described the unusual chemical properties of this substance, which, unlike normal glycogen, showed a blue-violet color in the iodine–starch reaction and was resistant to alpha-amylase. Initially it was called 'hepatic amylopectinosis'.
In 1966, the biochemist D.H. Brown and colleagues analyzed the structure of this abnormal glycogen in detail and named it the 'polyglucosan body', with abnormally few branches and a predominantly linear-chain structure. It was hypothesized that because this structure consists of much longer and more linear chains than normal glycogen, it is difficult to degrade by lysosomal enzymes and is recognized as foreign material within the cell, triggering an immune response.
In the 1980s, deficiency of glycogen branching enzyme (GBE), the enzyme responsible for branching during glycogen synthesis, was confirmed as the cause of GSD IV. In 1989, a separate clinical syndrome in adults, whose main phenotype is nervous system involvement due to GBE1 deficiency, was independently described and named 'adult polyglucosan body disease (APBD)'. APBD shows a phenotype clinically completely different from classic Andersen disease in that it first presents with neurological symptoms in the 40s–60s without liver symptoms in infancy or childhood.
In 1993, Ebertl et al. cloned the GBE1 gene (3p12.3), and various pathogenic variants were subsequently reported in both APBD and classic GSD type IV. The APBD founder variant c.986A>C (p.Tyr329Ser) was identified in Ashkenazi Jews, explaining the high frequency of APBD in that population. Since the 2000s, liver transplantation has become the standard treatment for classic (hepatic) Andersen disease, and it has been confirmed that liver function is corrected after transplantation, but muscle and nerve involvement may persist or progress. Currently, GBE1 gene-based enzyme replacement therapy and AAV gene therapy are at the preclinical research stage.
Andersen disease (GSD type IV) is an autosomal recessive genetic disease caused by deficiency of glycogen branching enzyme (GBE; EC 2.4.1.18) due to pathogenic variants in the GBE1 gene. GBE is responsible for forming α-1,6 branches on linear chains during glycogen synthesis. Specifically, GBE cleaves the end of a chain containing 6–7 glucose residues from a linear glycogen chain and transfers it to an α-1,6 linkage position on an adjacent chain, thereby forming a branched structure. This branching is essential for glycogen to maintain a water-soluble, compact structure, and allows glycogen phosphorylase and debranching enzyme to degrade it efficiently.
When GBE is deficient, branches are not formed during glycogen synthesis, and a polysaccharide with an abnormally linear chain structure is synthesized. This abnormal polysaccharide is structurally similar to amylopectin (the main component of plant starch) and is called a 'polyglucosan body'; unlike normal glycogen, it has increased resistance to degrading enzymes (amylase, phosphorylase) and accumulates within cells. In addition, this abnormal material is strongly positive on PAS (periodic acid-Schiff) staining, and its deep blue-violet color in the iodine–starch reaction is a histochemical feature that distinguishes it from normal glycogen (brown).
The intracellular accumulation of polyglucosan bodies goes beyond simple physical accumulation: they are recognized as foreign material, triggering immune and inflammatory responses, which lead to hepatic inflammation, fibrosis, and cirrhosis. The same mechanism operates in muscle, myocardium, and nerve cells, causing a variety of clinical phenotypes.
The degree of residual GBE1 activity and the location and type of the specific variant are the main determinants of the clinical phenotype. Loss-of-function variants with almost no residual activity (homozygous or compound heterozygous) result in the classic infantile/childhood hepatic form, whereas missense variants that retain some residual activity present as APBD, in which nervous system involvement comes to the fore without liver symptoms until adulthood. The diversity of this phenotypic spectrum is a molecularly interesting feature of Andersen disease/GSD type IV.
The GBE1 gene is located on chromosome 3p12.3, spans about 200 kb in total, and consists of 16 exons. Its translation product is a 702-amino-acid glycogen branching enzyme. More than about 80 pathogenic variants have been reported worldwide, including various types such as missense, nonsense, splicing, small deletions, and large copy number variants (CNV).
Classic hepatic form GSD IV: a severe phenotype presenting with liver cirrhosis and liver failure in infancy, often with loss-of-function variants (nonsense, frameshift, splicing, large deletions) on both alleles. There is almost no residual GBE activity, so polyglucosan body accumulation is severe.
Neonatal neuromuscular variant: presents at birth with severely decreased fetal movement, generalized hypotonia, and respiratory failure, and in some cases hydrops fetalis is observed. It is characterized by extensive polyglucosan deposition in the myocardium and skeletal muscle. Most die in the neonatal period.
APBD (adult polyglucosan body disease): a phenotype presenting with neurological symptoms in adults in their 40s–60s, a pattern in which some residual GBE1 activity is preserved so that clinical symptoms of the liver and muscle do not appear or are mild, while polyglucosan body accumulation in nerve cells progresses. In Ashkenazi Jews, the c.986A>C (p.Tyr329Ser) founder variant is found on one or both alleles, and in this population the APBD carrier frequency is estimated at about 1/100 and the prevalence at about 1/10,000. Various variant combinations have been reported in non-Jewish APBD.
Phenotype–genotype correlation: the clinical phenotype varies even with the same variant, so prediction is not complete. Genetic modifier effects, secondary genetic factors, and environmental factors are presumed to contribute. There is phenotypic diversity even among patients homozygous for p.Tyr329Ser, with some showing mild liver symptoms and others showing purely neurological symptoms. Next-generation sequencing (NGS)-based analysis of the entire GBE1 gene is currently the diagnostic standard.
Andersen disease (GSD type IV) is the rarest subtype of glycogen storage disease, accounting for about 3% of all GSD, with a prevalence estimated at about 1 in 600,000–1,000,000 births. It is so rare that only a few hundred cases have been reported in the literature worldwide. There is no difference by sex.
Classic (hepatic) GSD IV is rarely reported worldwide, and founder effects in specific ethnic groups are more prominent in APBD than in the classic form. APBD occurs at a relatively higher frequency in Ashkenazi Jews than in other ethnic groups owing to the c.986A>C (p.Tyr329Ser) founder variant. The carrier frequency of this variant among Ashkenazi Jews is estimated at about 1/100, and the prevalence of APBD in this population is about 1/10,000, higher than in other ethnic groups. Non-Jewish APBD is reported as rare sporadic cases.
In Korea, there are almost no systematic epidemiological data on Andersen disease, with only a few case reports. GSD IV should be included in the differential diagnosis of infantile cirrhosis of unknown cause, and if PAS-positive polyglucosan bodies are found on liver biopsy, the diagnosis is confirmed by GBE enzyme testing and GBE1 gene analysis. Most APBD patients present to adult neurology outpatient clinics with neuropathy of unknown cause with upper and lower motor neuron abnormalities, and diagnosis is often delayed because awareness of the rare disease is low.
Because GSD IV is not included in newborn screening, patients with the classic form are diagnosed after symptoms appear. Since the clinical benefit of early diagnosis through newborn screening has not been clearly demonstrated for the classic form, early diagnosis based on family history and rapid enzyme and genetic confirmation according to clinical symptoms are the realistic strategy.
The core pathophysiology of Andersen disease (GSD type IV) is the accumulation of polyglucosan bodies (PGB) due to GBE deficiency and the resulting cell damage. In normal glycogen synthesis, glycogen synthase elongates linear chains by adding glucose with α-1,4 linkages, and GBE periodically cleaves 6–7 residues from the chain end to create branches with α-1,6 linkages. As a result, normal glycogen becomes a compact, water-soluble structure with branches at intervals of about 8–12 glucose units.
When GBE is deficient, branches are not formed and glycogen chains only keep elongating. As a result, PGB with an abnormally long linear-chain structure resembling amylopectin (plant starch) is formed. Unlike normal glycogen, PGB shows ① high insolubility leading to intracellular aggregation, ② PAS positivity (strong purple), ③ a blue-violet iodine reaction, ④ alpha-amylase resistance, and ⑤ immunogenicity (recognized as foreign material, inducing an inflammatory response that attracts monocytes, macrophages, and lymphocytes).
Hepatic pathophysiology: PGB accumulation within hepatocytes and the resulting inflammatory response progress to rapid liver fibrosis and cirrhosis through activation of Kupffer cells and stimulation of hepatic stellate cells. It is characterized by a rapid clinical course in which substantial cirrhosis has already formed in infancy, leading to liver failure.
Neuromuscular pathophysiology: when PGB accumulates in nerve cells, especially in axons and Schwann cells, impaired axonal conduction and demyelination occur. PGB deposition in spinal anterior horn cells and the corticospinal tract also causes upper and lower motor neuron dysfunction. PGB deposition in the autonomic nerves of the bladder and bowel also causes dysfunction (bladder overactivity, urinary incontinence). In APBD, this nerve damage progresses gradually over decades.
Role of immune-mediated mechanisms: it has been hypothesized that an immune-mediated mechanism, in which PGB itself is recognized as foreign material and induces an inflammatory response by macrophages and T cells, is an important factor determining the rate of cirrhosis. After liver transplantation, the graft (donor liver) has normal GBE, so PGB production in the liver stops and liver symptoms are corrected, but PGB in muscle and nerves is not removed by liver transplantation, so abnormalities in these sites persist.
In Andersen disease (GSD type IV), the age of onset and main symptoms differ greatly according to the clinical subtype.
Classic hepatic form: the most common clinical phenotype, in which hepatomegaly and failure to thrive appear as initial symptoms in infancy (6–18 months of age). Over the following months to years, liver cirrhosis, portal hypertension, ascites, esophageal varices, and splenomegaly develop. Hypoglycemia is mild or absent. Some patients have accompanying hypertrophic cardiomyopathy. Without treatment, most die of liver failure before age 5, and this process often progresses rapidly within 2–3 years.
Neonatal neuromuscular variant: presents around birth with severely decreased fetal movement (loss of fetal movement), generalized hypotonia at birth, and immediate respiratory failure. In severe cases, hydrops fetalis develops. Cardiomyopathy is present, and most die in the neonatal period.
Myopathic variant: muscle weakness and exercise intolerance in childhood are the main symptoms, with no or mild liver involvement. Hypertrophic cardiomyopathy is sometimes present.
Adult polyglucosan body disease (APBD): presents in the 40s–60s, and the main symptoms are ① progressive limb spasticity and weakness (coexisting upper and lower motor neuron abnormalities — spasticity from corticospinal tract involvement + weakness and atrophy from anterior horn cell/peripheral nerve involvement), ② bladder dysfunction (urinary urgency, urinary incontinence, voiding difficulty), ③ peripheral neuropathy (sensory loss, numbness, tingling in the toes), ④ cognitive decline and dementia (progressing in some patients), and ⑤ gait abnormalities (spastic gait, impaired coordination). Liver symptoms are absent or mild.
Physical signs of the classic (hepatic) form: hepatomegaly (lower liver edge palpable several cm or more below the costal margin, hard texture — a sign of advancing fibrosis), splenomegaly (when portal hypertension develops), ascites (as cirrhosis progresses), jaundice (as liver failure progresses). In infancy, failure to thrive (low weight and height) is prominent. Cardiomegaly may be palpable or a heart murmur may be heard on auscultation (when cardiomyopathy is present).
Laboratory findings (classic form): elevated AST, ALT, GGT, and ALP (hepatocellular injury and cholestasis), abnormal serum albumin and prothrombin time (reduced liver function), thrombocytopenia (increased splenic sequestration). Blood glucose is generally normal, but hypoglycemia occurs in advanced liver failure. CK is elevated in the myopathic variant and normal or mildly elevated in the hepatic form.
Histological findings: liver biopsy shows massive deposition of PAS-positive material within hepatocytes, distributed within cells in a zymogram pattern. It shows a blue-violet color (abnormal glycogen) with iodine solution. Histological findings of fibrosis starting in the periportal area and progressing to bridging fibrosis and cirrhosis are confirmed.
Neurological signs of APBD: spastic paralysis of the limbs (spastic paraparesis or tetraparesis) together with muscle atrophy and weakness (mixed upper and lower motor neuron signs), hyperactive deep tendon reflexes (corticospinal tract involvement) or absent reflexes (when peripheral nerve involvement predominates), pathological reflexes (Babinski positive), and reduced bladder filling or reflex overactivity (abnormal urodynamic study). Nerve conduction studies show a sensorimotor neuropathy pattern (reduced conduction velocity, reduced amplitude). Extensive white matter abnormalities (leukoencephalopathy) on brain MRI are characteristic.
There is no standardized universal newborn screening for Andersen disease (GSD type IV). Early diagnosis through clinical suspicion, biochemical testing, and enzyme activity measurement is the realistic approach.
Screening clues for the classic form: cirrhosis or hepatomegaly of unknown cause arising in infancy requires a differential diagnosis that includes GSD IV, Wilson disease, biliary atresia, alpha-1 antitrypsin deficiency, and others. If PAS-positive granular deposits are found on liver biopsy, GSD IV is strongly suggested. Measurement of leukocyte GBE enzyme activity allows rapid biochemical confirmation.
Screening clues for APBD: APBD should be considered in adults (in their 40s–60s) when there is a combination of ① mixed upper and lower motor neuron signs (an ALS-like phenotype but with bladder dysfunction), ② peripheral neuropathy, ③ white matter abnormalities on brain MRI, and ④ bladder dysfunction. Unlike ALS, bladder dysfunction is prominent from the early stage in APBD, and brain white matter abnormalities on MRI are present, which are differentiating clues. When neuropathy develops in an Ashkenazi Jewish adult, APBD must be included in the differential list. GBE1 gene analysis (particularly testing for the c.986A>C variant) is appropriate as an early screening test.
Family history-based screening: in subsequent pregnancies of families who have had a child with GSD IV, prenatal genetic diagnosis or enzyme activity measurement is possible. Preventing implantation of affected embryos through PGT is also an option.
The diagnosis of Andersen disease (GSD type IV) combines clinical symptoms, enzyme activity measurement, histology, and molecular genetic confirmation.
GBE enzyme activity measurement: GBE activity is measured in leukocytes, fibroblasts, erythrocytes, or liver/muscle tissue. A decrease in GBE activity to less than 10% of normal contributes to confirmation. In APBD, some residual GBE activity may be preserved (10–50% of normal), so more caution is needed in interpreting results than in the classic form. Leukocyte GBE activity is reduced in both the hepatic form and APBD, making it useful as a noninvasive confirmatory tool.
GBE1 gene analysis: analysis of the 16 exons and intron boundaries of GBE1 + CNV analysis is performed. Identification of variants on both alleles confirms the diagnosis and also helps predict the phenotype (hepatic form vs APBD). In APBD, identification of c.986A>C (p.Tyr329Ser) homozygosity or compound heterozygosity confirms the diagnosis in Ashkenazi Jews.
Liver biopsy and histology: strongly positive material within hepatocytes on PAS staining (some remaining even after α-amylase treatment), and blue-violet material in the iodine–starch reaction. On electron microscopy, glycogen particles with an abnormally long linear-chain structure. Assessment of the degree of liver fibrosis (Metavir or Ishak score).
Diagnosis of APBD: identification of PAS-positive PGB in sweat glands and around nerves on skin biopsy is a relatively noninvasive diagnostic method. PGB is also identified on rectal or peripheral nerve biopsy. Extensive white matter abnormalities on brain and spinal cord MRI are characteristic. The diagnosis is confirmed by GBE1 gene analysis together with nerve conduction study and electromyography findings.
There is currently no specific enzyme replacement therapy or approved drug treatment for Andersen disease (GSD type IV). In the classic (hepatic) form, liver transplantation is the only definitive treatment, and in the neuromuscular variant and APBD, symptomatic treatment is the mainstay.
Liver transplantation (classic form): in the hepatic form of GSD IV, liver transplantation is the only established treatment that corrects liver symptoms. After transplantation, the grafted liver with normal GBE activity blocks PGB production in the liver, so liver function normalizes and survival is greatly prolonged. Timing of liver transplantation: early transplantation is recommended before cirrhosis worsens or signs of liver failure appear. However, because liver transplantation does not correct GBE deficiency in muscle and nerves, progression of cardiomyopathy and myopathy has been reported even after transplantation. There are reports of cardiomyopathy improving after liver transplantation in some cases, and research is being conducted on the secretion of liver-derived GBE (the possibility of systemic delivery).
Symptomatic treatment — neuromuscular variant: mechanical ventilatory support for neonatal respiratory failure. Standard heart failure treatment for cardiomyopathy. Most die in the short term, so experience with long-term treatment is limited.
Treatment of APBD: without specific treatment, symptom management is central. ① Treatment of spasticity: antispasticity drugs such as baclofen and tizanidine. ② Bladder dysfunction: anticholinergics, clean intermittent self-catheterization. ③ Peripheral neuropathy: management of neuropathic pain (gabapentin, pregabalin). ④ Rehabilitation: maintaining mobility with physical and occupational therapy. There is a small study showing that triheptanoin (providing energy dependent on seven-carbon medium-chain fat) relieved neurological symptoms in some patients, but it has not been established as standard treatment. Insulin-like growth factor-1 (IGF-1) has been studied preclinically, but its effect in humans is not established.
Gene therapy: AAV8- or AAV9-based GBE1 gene delivery is being studied in animal models. In the hepatic form, systemic correction is theoretically expected to be possible by delivering GBE to the liver, muscle, and nerves, but it has not yet entered the clinical trial stage.
The prognosis of Andersen disease (GSD type IV) differs greatly according to the clinical phenotype.
Prognosis of the classic (hepatic) form: without liver transplantation, most patients die of liver failure or complications before age 5. The rate of cirrhosis, which progresses rapidly in infancy, directly affects prognosis. Survival after liver transplantation is about 80% or more at 5 years, similar to liver transplantation for other pediatric liver diseases. However, cardiomyopathy and myopathy may persist or progress even after liver transplantation, and in some, cardiomyopathy becomes the main cause of morbidity within several years after transplantation. A non-progressive form in which liver function is maintained for years despite cirrhosis has been reported in some GSD IV patients, and there is discussion about whether early liver transplantation is necessarily needed in all patients.
Prognosis of the neuromuscular variant: most cases of the neonatal-onset form die in the neonatal period, and the prognosis is very poor. Despite mechanical ventilation, cardiopulmonary function continues to deteriorate, and death often occurs within days to weeks.
Prognosis of APBD: a slowly progressive neurological disease in which loss of walking ability (wheelchair use) and progression of dementia occur over 10–15 years after onset. Bladder complications (recurrent urinary tract infections, reduced kidney function) are an important cause of morbidity. Overall life expectancy into the 60s–70s is possible, but quality of life gradually declines.
Primary prevention of Andersen disease (GSD type IV) is achieved through genetic counseling and genetic testing. In families who have previously had a child with GSD IV, affected births can be prevented through prenatal genetic diagnosis (CVS or amniocentesis, at 11–20 weeks of gestation) or PGT. Because the risk of APBD is high in the Ashkenazi Jewish population, it is clinically meaningful to provide GBE1 gene testing and genetic counseling before marriage or at the pregnancy planning stage.
Preventive approach in the hepatic form: deciding the timing of early liver transplantation is key to preventing liver failure. Early transplantation is considered before cirrhosis worsens, to minimize surgical risk and maximize survival. Regular follow-up to prevent adverse effects of post-transplant immunosuppressive therapy (infection, reduced kidney function) is important. Regular electrocardiography and echocardiography for cardiomyopathy monitoring.
Preventive approach in APBD: early detection of bladder dysfunction to prevent recurrent urinary tract infections and reduced kidney function. Training in clean intermittent self-catheterization and administration of anticholinergics. Maintaining mobility as much as possible and reducing fall risk through physical therapy and rehabilitation. Stretching exercises and appropriate use of antispasticity drugs to prevent worsening of spasticity. Periodic neuropsychological assessment for cognitive decline and planning of support for daily activities.